Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor b (TGF-b) and PDL1

Category Primary study
JournalAnnals of Oncology
Year 2018
This article has no abstract
Epistemonikos ID: a9bc2518ea3264998f051dfd3b830393c388c5ed
First added on: Feb 11, 2025